C-peptide Concentrations in Type 2 Diabetes Treated With Insulin; is it Time to Revise the Treatment of Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

249 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-01

Study Completion Date

2019-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

C-peptide is used to evaluate beta cell reserves. Patients with type 2 diabetes are treated with insulin for different indications. Other than beta-cell insufficiency and organ failures, insulin treatment is needed for a specified period. The investigators want to evaluate beta cell reserves in patients with type 2 diabetes treated with insulin for at least six months to see if that is the case. The investigators also want to compare the characteristics of these patients according to their beta cell reserves.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

β-cell Function in Type 1 Diabetes May Not Be As Low As Presumed

NCT02199470

TYPE 1 DIABETES

COMPLETED

Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes

NCT06825182

Type 2 Diabetes Mellitus

RECRUITING PHASE3

The Effect of Roux-en-Y Gastric Bypass on Insulin Sensitivity in Type 2 Diabetes

NCT01202526

Type 2 Diabetes Obesity

COMPLETED

Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and Graded Intravenous Infusion

NCT03223129

Type 2 Diabetes Mellitus

COMPLETED NA

Beta-Cell Function After Near-Normalisation of Blood Glucose

NCT00612950

Type 2 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In patients with type 2 diabetes, initiation of insulin therapy is indicated in several conditions such as severe insulin resistance, acute metabolic decompensations, surgery, pregnancy, and progression of diabetic complications, and also when glycemic control cannot be achieved with effective lifestyle regulation and non-insulin antidiabetic medications. Some of these indications are transient, and patients should be reassessed to choose the appropriate treatment options. Clinical inertia is one of the new topics expressed in the recent diabetes guidelines. The investigators aimed to investigate the beta cell reserves of the patients with type 2 diabetes who are treated with insulin, to see if they have insufficient insulin secretion and if not, to compare their characteristics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Treated With Insulin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with type 2 diabetes treated with insulin

Patients with type 2 diabetes who have been using insulin for at least six months.

They should be older than 18 years The patients should be presented to the Diabetes Outpatient Clinics of Istanbul Medeniyet University Goztepe Training and Research Hospital

C-peptide concentrations

Intervention Type DIAGNOSTIC_TEST

The patients will be grouped by their C-peptide concentrations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

C-peptide concentrations

The patients will be grouped by their C-peptide concentrations

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with type 2 diabetes who had been treated with insulin as a monotherapy or as a component of combination therapy for at least 6 months.

Exclusion Criteria

* Diagnosis of other types of diabetes,
* end-stage renal failure,
* history of renal transplantation,
* diabetic acute metabolic decompensation,
* decompensated heart failure,
* advanced liver disease,
* pregnancy,
* acute or chronic pancreatitis,
* pancreatic carcinoma,
* acute infections,
* use of medications that might affect glucose regulation (e.g. corticosteroids)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No